StreetInsider.com News Articles

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

PHILADELPHIA--(BUSINESS WIRE)-- Tolerance Bio, Inc. (“Tolerance Bio” or the “Company”), a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, today announced an exclusive license agreement with NeoImmuneTech (NIT, KOSDAQ: 950220.KQ) for the development and commercialization of efineptakin alfa (also known as NT-I7), a clinical-stage long-acting IL-7

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

Wed, 19 Aug 2026 08:00:00 -0400

Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience

Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution

Emmaus Life Sciences Announces Strategic Transaction